Our first lead candidate combines HER2 targeting with a novel proteasome inhibition mechanism of action that has never been used in the ADC landscape previously. With the potential for substantially improved tolerability, enhanced efficacy and a once-monthly dosing profile, this lead program aspires to substantially augment the therapeutic armamentarium for solid cancers. In early pre-clinical studies, ABC-007 yielded improvement in efficacy in solid cancer models that other mainstream ADCs are unable to treat.
This program is the focus of a collaboration with the Nanotechnology Characterization Laboratory (NCL) division of the National Cancer Institute (NCI). By fundamentally altering the intrinsic therapeutic window for proteosome inhibition to induce cancer cell death, the potential for treatment of a variety of solid tumor malignancies such as lung, breast and even pancreatic cancer – heretofore infeasible – is being explored as part of the ABC-007 development program.